Revenue generating with marine-derived and novel MoA oncology products. 2018 total revenues of €162M. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Zepsyre (lurbinectedin), optimized analog of Yondelis, reported positive Ph 2 results - company will file its NDA under accelerated approval for lurbinectedin monotherapy for the treatment of relapsed SCLC during Q4, 2019, with potential approval and US launch in 2020.
Platform Technology, Small Molecule
Plaza del Descubridor Diego de Ordás 3
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by